IN2013MU03596A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03596A
IN2013MU03596A IN3596MU2013A IN2013MU03596A IN 2013MU03596 A IN2013MU03596 A IN 2013MU03596A IN 3596MU2013 A IN3596MU2013 A IN 3596MU2013A IN 2013MU03596 A IN2013MU03596 A IN 2013MU03596A
Authority
IN
India
Prior art keywords
solvent
dehalogenated
formation
minimising
present
Prior art date
Application number
Inventor
Shashikant Kadam
Rajshekar Araddy
Venkateswara Kondragunta
Yogesh Hulavale
Narender Rao Somisetti
Suneel Manohar Babu Chennamsetty
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Priority to IN3596MU2013 priority Critical patent/IN2013MU03596A/en
Priority to PCT/IB2014/065978 priority patent/WO2015071831A1/en
Publication of IN2013MU03596A publication Critical patent/IN2013MU03596A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention provides an improved process for preparation of organic compounds represented by Formula-Z; wherein effectively minimising the formation of dehalogenated by-products is achieved. In the process, the reduction is carried out using suitable reducing agent; more preferably Lithium Aluminium Hydride (LAH) in a solvent system, wherein at least one of the solvent is selected from halogenated solvents, which acts as co-solvent. The process of the present invention is useful for minimising of the formation of dehalogenated by-products during synthesis of various active pharmaceutical ingredients such as Paroxetine Hydrochloride, Cinacalcet, Eletriptan and Asenapine.
IN3596MU2013 2013-11-18 2014-11-12 IN2013MU03596A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3596MU2013 IN2013MU03596A (en) 2013-11-18 2014-11-12
PCT/IB2014/065978 WO2015071831A1 (en) 2013-11-18 2014-11-12 An improved process for minimising the formation of dehalogenated byproducts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3596MU2013 IN2013MU03596A (en) 2013-11-18 2014-11-12

Publications (1)

Publication Number Publication Date
IN2013MU03596A true IN2013MU03596A (en) 2015-07-24

Family

ID=53056868

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3596MU2013 IN2013MU03596A (en) 2013-11-18 2014-11-12

Country Status (2)

Country Link
IN (1) IN2013MU03596A (en)
WO (1) WO2015071831A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
MX2019007391A (en) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3680184D1 (en) * 1985-08-10 1991-08-14 Beecham Group Plc METHOD FOR PRODUCING ARYLPIPERIDINE CARBINOL.
NZ307479A (en) * 1995-05-17 1999-08-30 Novo Nordisk As A process for preparing 4-(4-halo substituted phenyl)-3-(3,4-methylenedioxy phenoxy methyl)piperidine derivatives
US6444190B2 (en) * 1995-08-03 2002-09-03 Fmc Corporation Reduction compositions and processes for making the same
JP3446468B2 (en) * 1996-04-15 2003-09-16 旭硝子株式会社 Method for producing piperidine carbinols
WO2008058235A2 (en) * 2006-11-08 2008-05-15 Dr. Reddy's Laboratories, Ltd. Processes for the preparation of cinacalcet

Also Published As

Publication number Publication date
WO2015071831A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
MX2009008541A (en) Hcv inhibiting macrocyclic phenylcarbamates.
MX363127B (en) Benzothiophene derivatives as estrogen receptor inhibitors.
IN2014KN00948A (en)
MX2009008540A (en) Pyrimidine substituted macrocyclic hcv inhibitors.
JO3494B1 (en) Benzothiophene derivatives and and compositions thereof as selective estrogen receptor degraders
MX2015008975A (en) Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions.
JO3530B1 (en) 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
MX2015005858A (en) Dihydropyrazole gpr40 modulators.
TN2016000556A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2015003594A (en) Therapeutic or prophylactic agent for tumor lysis syndrome.
MX362383B (en) Oxabicyclo [2.2.2] acid gpr120 modulators.
PH12016502034B1 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
MX2015005735A (en) Dihydropyrazole gpr40 modulators.
IN2013MU03596A (en)
MX2015011932A (en) Bicyclo [2.2.2] acid gpr120 modulators.
PH12016502246A1 (en) Carboxamide derivatives
MX2016014946A (en) Carboxamide derivatives.
MX2015011375A (en) Bicyclo [2.2.1] acid gpr120 modulators.
SG194696A1 (en) Isoxazolines as therapeutic agents
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MY196804A (en) Class of bifunctional compounds with quaternary ammonium salt structure
MX2016005287A (en) Methods for treatment of muscular dystrophies.